IMMUNODEFICIENCY RETROVIRUSES IN MAN AND ANIMALS

医学、兽医学校和灵长类动物的研究人员 加州大学戴维斯分校(UCD)中心迫使 人类艾滋病和类艾滋病研究合作小组 动物中的疾病。这个多学科小组现在包括 15名首席调查员和大约 每年400万美元，主要来自美国国立卫生研究院和加州政府的37项拨款 加利福尼亚。该集团的打算是在大约2年内成为 年成为独立的、有组织的艾滋病研究和研究中心 加州大学系统内的疫苗学。这个 该小组的总体研究目标是了解自然 猴、猫和人类艾滋病的历史和发病机制 利用这些模型开发有效的逆转录病毒疗法 和疫苗。在不久的将来，我们计划继续研究 SRV、SIV和FILV诱导的免疫抑制，整合了我们的基础 和临床艾滋病毒研究工作，以继续我们的SIV和艾滋病毒 疫苗努力并在SIV细胞中开发新的计划 免疫学和HIV/SIV转基因小鼠。 此CFAR应用程序由一个管理单元3核心组成 A)临床病毒学，B)灵长类中心，C)分子 病毒学和两个可自由支配/发展领域：1)艾滋病毒/艾滋病毒 2)SIV细胞免疫学。

Investigators in the Medical and Veterinary Schools and Primate Center at University of California, Davis (UCD) have forced a Cooperative Group for research on AIDS in human and AIDS-like disease in animals. This multidisciplinary group now consists of 15 Principal Investigators and a funding base of approximately 4M/year primarily from 37 grants from NIH and the State of California. The intention of the Group is to become in about 2 years an independent, organized Center for AIDS Research and Vaccinology within the University of California system. The overall research goals of the Group are to understand the natural history and pathogenesis of simian, feline and human AIDS and to use these models for development of effective retroviral therapies and vaccines. In the near future we plan to continue research on SRV, SIV and FILV induced immunosuppression, to integrate our basic and clinical HIV research efforts, to continue our SIV and HIV vaccine efforts and to develop new programs in SIV cellular immunology and HIV/SIV transgenic mice. This CFAR application consists of an Administration Unit three core components, A) Clinical Virology, B) Primate Center, C) Molecular Virology and two discretionary/developmental areas, 1) HIV/SIV transgenic mice and 2) SIV Cellular Immunology.